ClinicalTrials.gov record
Active, not recruiting Phase 2Phase 3 Interventional

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

ClinicalTrials.gov ID: NCT04057898

Public ClinicalTrials.gov record NCT04057898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis

Study identification

NCT ID
NCT04057898
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
MediciNova
Industry
Enrollment
234 participants

Conditions and interventions

Interventions

  • MN-166 Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 27, 2020
Primary completion
Mar 31, 2027
Completion
Mar 31, 2028
Last update posted
Mar 5, 2026

2020 – 2028

United States locations

U.S. sites
10
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
University of California Orange California 92868
Mayo Clinic Jacksonville Florida 32224
Augusta University Augusta Georgia 30912
Indiana University IU Health Neuroscience Center Indianapolis Indiana 46202
Johns Hopkins University Baltimore Maryland 21287
Hennepin Healthcare Research Institute Minneapolis Minnesota 55415
SUNY Upstate Medical University Syracuse New York 13210
Duke University Durham North Carolina 27705
Lehigh Valley Health Network Allentown Pennsylvania 18103
University of Virginia Health System Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04057898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2026 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04057898 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →